Global Retirement Partners LLC Takes $1.40 Million Position in DexCom, Inc. $DXCM

Global Retirement Partners LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, Holdings Channel reports. The fund purchased 20,784 shares of the medical device company’s stock, valued at approximately $1,400,000.

Several other institutional investors and hedge funds also recently modified their holdings of DXCM. Reflection Asset Management bought a new position in DexCom in the 4th quarter valued at about $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC bought a new stake in shares of DexCom during the 4th quarter worth about $32,000. Wellington Grp LLC lifted its stake in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares during the period. Finally, DV Equities LLC acquired a new stake in shares of DexCom in the 4th quarter worth approximately $36,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 1.1%

Shares of DexCom stock opened at $88.76 on Tuesday. The stock has a 50-day simple moving average of $76.32 and a 200-day simple moving average of $70.44. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $91.96. The firm has a market cap of $33.49 billion, a price-to-earnings ratio of 35.08, a P/E/G ratio of 1.51 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the firm earned $0.48 EPS. DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jon Coleman sold 4,911 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the transaction, the executive vice president directly owned 95,450 shares in the company, valued at $7,075,708.50. This represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the transaction, the director directly owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 99,794 shares of company stock worth $7,373,321 over the last three months. 0.28% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. TD Cowen reiterated a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Stifel Nicolaus set a $95.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.